Literature DB >> 14751085

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Arthur M Krieg1.   

Abstract

Tumor immunotherapy has evolved from the use of crude bacterial extracts to chemically synthesized ligands for specific immune receptors, such as Toll-like receptors (TLRs). One of the most promising targets for therapeutic immune activation is TLR9, which detects unmethylated CpG dinucleotides present in viral and prokaryotic genomes, which are generally methylated in host DNA. This review describes the immune effects of synthetic CpG oligonucleotides as TLR9 ligands and their applications in cancer immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14751085     DOI： 10.1007/s11912-004-0019-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  71 in total

1.  CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha.

Authors:  Sue E Blackwell; Arthur M Krieg
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

2.  Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

Authors:  S K Kim; G Ragupathi; C Musselli; S J Choi; Y S Park; P O Livingston
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

3.  The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

4.  CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses.

Authors:  G B Lipford; T Sparwasser; S Zimmermann; K Heeg; H Wagner
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

5.  Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients.

Authors:  B R Blazar; A M Krieg; P A Taylor
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

Authors:  T R Jones; N Obaldia; R A Gramzinski; Y Charoenvit; N Kolodny; S Kitov; H L Davis; A M Krieg; S L Hoffman
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

7.  CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.

Authors:  H L Davis; I I Suparto; R R Weeratna; D D Iskandriati; S S Chamzah; A A Ma'ruf; C C Nente; D D Pawitri; A M Krieg; W Smits; D D Sajuthi
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

8.  CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.

Authors:  T L Warren; C E Dahle; G J Weiner
Journal:  Clin Lymphoma       Date:  2000-06

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.

Authors:  Alain P Vicari; Claudia Chiodoni; Céline Vaure; Smina Aït-Yahia; Christophe Dercamp; Fabien Matsos; Olivier Reynard; Catherine Taverne; Philippe Merle; Mario P Colombo; Anne O'Garra; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307
View more
  45 in total

1.  Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Authors:  Sakineh Pirahmadi; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Abbas-Ali Raz; Jafar J Sani
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 3.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

4.  Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes.

Authors:  H W Xiao; Y Luo; X Y Lai; J M Shi; Y M Tan; J S He; W Z Xie; W Y Zheng; X J Ye; X H Yu; Z Cai; M F Lin; H Huang
Journal:  Bone Marrow Transplant       Date:  2013-10-14       Impact factor: 5.483

5.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

Review 6.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 7.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 8.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

9.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma.

Authors:  Lisa Elefanti; Giorgia Sacco; Camilla Stagni; Marco Rastrelli; Chiara Menin; Irene Russo; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.